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TCGAS100P signaling through the receptor for advanced glycation end-products (RAGE) contributes to
colon cancer invasion and metastasis, but the mechanistic features of this process are obscure.
Here, we investigate whether activation of S100P/RAGE signaling regulates oncogenic
microRNA-21 (miR-21). We show that exogenous S100P up-regulates miR-21 levels in human colon
cancer cells, whereas knockdown of S100P results in a decrease of miR-21. Furthermore, blockage of
RAGE with anti-RAGE antibody suppresses S100P induction of miR-21. In addition, we found that
S100P induction of miR-21 expression involves ERK and is suppressed by the MEK inhibitor
U0126. Also, S100P treatment stimulates the enrichment of c-Fos, and AP-1 family members, at
the miR-21 gene promoter.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Approximately half of the patients diagnosed with colon cancer
will develop liver metastasis [1]. Metastasis is the major cause of
death in cancer patients and is largely considered incurable due
to a lack of effective therapy other than hepatic resection [2,3].
Metastasis is a complex multi-factorial and multi-step process
which promotes the detachment, migration, and proliferation of
malignant lesions from the primary tumor site to distant site
[4,5]. Deﬁning the gene targets underlying the metastatic process
is essential for the development of an effective targeted therapy
[6].Inﬂammation plays a direct role in colorectal cancer progres-
sion. Several studies show that inﬂammation is associated with
cancer progression and an increased inﬁltration of inﬂammatory
cells and inﬂammatory molecules/factors are present in colon can-
cers during tumor progression (reviewed in Terzic et al. [7]).
Recent studies by our group and others indicate that S100P is an
important mediator of cancer related inﬂammation [8–10].
Extracellular S100P can act as a ligand for the receptor for
advanced glycation endproducts (RAGE) and activate key signaling
pathways such as extracellular regulated kinases (ERK1/2), NF-kB,
and the JAK/STAT pathway [10–12]. S100P levels are increased in
several cancers including colon cancers and are associated with
metastasis [13]. Downstream target within the S100P/RAGE signal-
ing pathway that contribute to cancer progression remain an active
area of investigation.
Furthermore, the mechanistic linkage between inﬂammation
and colon cancer progression remain to be elucidated. Recent stud-
ies indicate that microRNA (miRNAs) dysregulation represents a
potential molecular mechanism for inﬂammatory pathways to
mediate cancer development and progression [14]. Speciﬁcally,
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human cancers, including colon cancer [15]. Additional studies
have demonstrated an association between elevated levels of
miR-21 and down-regulation of several target genes such as pro-
grammed cell death 4 (PDCD4), tissue inhibitor of metallopro-
teinase 3 (TIMP3), phosphatase and tensin homolog (PTEN),
Sprouty, and reversion-inducing cysteine-rich protein with Kazal
motifs (RECK) [16–18]. Hence, these studies implicate miR-21 in
the participation of several key biological processes important in
the malignant phenotype. However, the factors that lead to the
dysregulation of miR-21 expression have not been fully explored.
In the present study, we investigate the effects of S100P/RAGE acti-
vation on the induction of miR-21 expression.2. Materials and methods
2.1. Cell culture, S100P over-expression and stable lentiviral knock-
down using shRNA
SW480 and LS174T human cancer cell lines were purchased
from the ATCC and cultured in complete DMEM medium (DMEM
1X, 10% FBS and penicillin/streptomycin). The cells were incubated
in humidiﬁed atmosphere of 5% CO2 at 37 C. We have previously
described the generation of cells overexpressing S100P and knock-
down of S100P in cells [8,9]. In regards to the generation of S100P
overexpressing cells, one million SW480 or LS174T cells in 2 mL of
OptiMEM medium were transfected according to instructions of
Lipofectamine 2000 (Invitrogen). Cells were selected with
500 lg/mL of G418 and S100P expression was conﬁrmed by
Western blots. To knockdown S100P levels in colon cancer cells,
lentiviral production for pLKO.1, pLK0.1/sh1-S100P and
pLK0.1/sh2-S100P and infection were performed according to the
RNAi Consortium protocol (http://www.broadinstitute.org/rnai/
trc). Envelope (pCMV-dR8.2 dvpr) and packaging (pCMV-VSV-G)
plasmids were obtained from ADDGENE Inc. The lentivirus parti-
cles were titrated by infecting one million LS174T cells with
15 lL, 25 lL, 50 lL, 100 lL, 250 lL and 500 lL particles. Cells were
selected with 2 lg/mL of puromycin. Conﬁrmation of S100P
knock-down expression was done by qRT-PCR and Western blot
analyses. Cells transduced with 100 lL of viral particles were used
for further experiments.
2.2. Expression and puriﬁcation of S100P
The expression and puriﬁcation of human recombinant S100P
protein was performed as previously described by our group [8].
Brieﬂy, full length human S100P cloned in pTRCHis2 vector was
transformed in T0P10 Escherichia coli (Invitrogen). His-S100P was
puriﬁed using the Probond resin column (Invitrogen) as described
by the manufacturer. Puriﬁed protein was concentrated with
AMICON centrifugal ﬁlters. SDS–PAGE and Western blotting con-
ﬁrmed purity of the protein.
2.3. RNA isolation and qRT-PCR analysis
The procedures for RNA isolation and qRT-PCR have been previ-
ously described by our group [8]. Small RNAs were isolated with
mirVana miRNA Isolation kit (Ambion) and total RNA was isolated
with Qiagen RNA isolation kit (Qiagen). First strand cDNA for
miR-21 and U6 were synthesized in the same reaction with
Reverse transcriptase (Fermentas) using 20 pmol of stem-loop RT
primer (miR-21: 50-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA
CTGGATACGACTCAACA-30, U6: 50-GTCGTATCCAGTGCAGGGTCCGA
GGTATTCGCACTGGATACGACAAAAATATG-30) and 0.5 lg of
miRNA. QRT-PCR was performed with cDNA representing 50 ngof miRNA/reaction in quadruplicates with forward primers only
and the LightCycler 480 SYBR Green I Master (Roche) mix. The
sequence of miR-21 forward primer was 50-GCCCGCTAGCTTATCA
GACTGATG-30 and for U6 is 50-GCGCGTGAAGCGTTC-30. Data were
normalized to U6 levels.
The binding of recombinant S100P to the RAGE was blocked
with anti-RAGE monoclonal antibody (R&D Systems) as previously
described by our group [8]. Two millions SW480 cells were seeded
overnight in plates with complete medium. Cells were starved
overnight in OptiMEM medium and incubated at 37 C, 5% CO2.
Next day, 40 lg/mL of anti-RAGE monoclonal antibody was added
and after 2 h 200 nM of hr-S100P was added to the cells. Cell were
pre-treated with blocking anti-RAGE antibody and then treated
with recombinant S100P for different time periods (0, 20 min,
1 h, 2 h, 24 h) followed by qRT-PCR to measure miR-21 induction
as described above.2.4. Western blot analysis
To determine the activation of ERK1/2, AP-1 and NF-kB by
S100P/RAGE signaling, two millions SW480 cells were plated over-
night in culture plates in complete medium. Next day, cells were
serum starved overnight in OptiMEM medium. The following
day, cells were treated with 200 nM of hr-S100P and retrieved at
different time intervals (0, 15 min, 30 min, 1 h and 2 h).
Activation of pERK1/2, p c-fos, and pNF-kB-p-p65 was determined
from protein extracts as previously describe [19].
2.5. Pharmacologic inhibition
Two millions SW480 cells were pre-treated with chemical inhi-
bitors for AP-1 and NF-kB signaling. Since ERK1/2 transcribes c-fos
and activates c-fos and c-jun (components of AP-1), we used
U0126 to inhibit AP-1 transcription and activity by inhibiting
ERK1/2, and CAY10512 to inhibit NF-kB [20]. One million cells
were seeded overnight in culture plates. Next day, cells were
pre-treated separately with 10 lM of U0126 for 30 min and with
0.5 lM of CAY10512 for an hour. Cells were treated with 100 nM
of hr-S100P for 24 h and control samples with DMSO. Cells were
harvested to determine miR-21 expression levels by qRT-PCR as
described above.
2.6. Luciferase assays
We obtained the luciferase wild-type (WT) and mutant con-
structs of the pri-miR-21 promoter from Dr. Heike Allgayer [16].
Brieﬂy, mutations of AP-1 are at positions 59/52 bp (AP-1-I),
166/159 bp (AP-1-II), 225/220 bp (AP-1-III), and at
656/663 (AP-1-IV). We used two mutant constructs, one con-
taining AP-1 mutations at AP-1/I, AP-1/II and AP-1/III, and the sec-
ond containing all AP-1 mutations (AP-1/I – AP-1/IV) and one
NF-kappa B mutation at 209/211. Five hundred thousand
cells/well were seeded in 12-well plates overnight at 37 C, 5%
CO2 in complete medium. Next day, transfections were performed
according to reagent, TranslT-LT1 (Mirus Bio LLC) instructions.
Co-transfection of each Fireﬂy luciferase construct with a Renilla
Luciferase control reporter vector (Promega) was done in replicas
of three. Plasmid control for the pri-miR-21 promoter constructs
was pGL3-Basic. Next day after transfection, 200 nM of hr-S100P
in complete medium was added to the cells and thereof every
24 h for 48 h. Cell homogenization and luciferase assays
were performed according to Dual-Luciferase Reporter Assay
System kit’s instructions (Promega). Luciferase activity was mea-
sured with Sirius Luminometer. Experiments were performed in
triplicates.
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ChIP assays were performed according to EpiSeeker ChIP
Kit-One Step (ABCAM) protocol using the c-fos and
phospho-NF-kB-p65 antibodies. One million SW480 cells were
seeded overnight in complete medium in culture dishes. Next
day, cells were stimulated with 200 nM hr-S100P for 24 h. Cells
were then rinsed with PBS, ﬁxed with 10% formaldehyde/PBS for
1 h and scraped into lysis buffer for chromatin immunoprecipita-
tion as described previously [19]. Binding of c-fos and
phospho-NF-kB-p65 to the pri-miR-21 promoter was measured
by qRT-PCR with SYBR Green and respective primers for AP-1
and NF-kB binding. We designed two sets of primers (AP-1(1)
and AP-1(2)) comprising the AP-1 regions mutated by
Mudduluru [16], AP-1 binding motifs, 50/45 bp, 59/52 bp,
66/159 bp, 656/663 bp, 692/698 bp, 701/705 bp, and
a motif after the TSS 26/33 bp. Primer set AP-1 (1) sequences are,
FW-1: 50-GCC TCC CAA GTT TGC TAA TG-30 and REV-1: 50-TGT
ACT CTG GTA TGG CAC AAA GA-30, and it includes AP-1 binding
motifs at AP-1/I, AP-1-II, AP-1-III (see Luciferase Assays above),
which are proximal to the transcription start site (TSS). Primer
set AP-1 (2) (FW-2: 50-GAG ATC AGG CCA TTG CAC TC-30 and
REV-2: 50-GCA ACA CTG CCT AAT GCT TG-30) includes the AP-1
binding motif AP-1-IV. Primers sequences for NF-kB (1) comprise
regions outside the promoter and were obtained from literature
[21]. NF-kB (2) primer sequences (FW: 50-CTA TCC CAA TCA TCT
CAG AAC AAG CTG TTA CTA-30 and REV: 50-GGA CAA TCT GTG
CGT CAT CCT TAT CC-30) comprise two NF-kB binding motifs at
positions 300/308 bp and 301/292 bp from the TSS within
the promoter region.
2.8. The cancer genome atlas data analysis (TCGA)
Exon expression analysis of S100P, RAGE, mir21 and RECK in
The Cancer Genome Atlas dataset of colorectal adenocarcinoma
(COADREAD) was performed by RNA sequencing (IlluminaHiSeq)
of primary colorectal tumors (n = 347) and normal solid tissues
(n = 47). Statistical analysis was performed using Student’s t-test
with Benjamini-Hochberg correction with P < 0.05 considered as
statistically signiﬁcant.
2.9. Statistical analysis
All experiments were performed at least in triplicates. Results
are presented as means of ±S.E.M. Statistical comparisons between
two groups were made using two-tailed unpaired Student’s t-test.
A P-value of <0.05 was considered statistically signiﬁcant. Any
P-value of <0.05 is denoted as ⁄, P-value of <0.01 as ⁄⁄, and
P-value of <0.001 denoted ⁄⁄⁄.
3. Results
3.1. S100P/RAGE up-regulates the expression of miR-21
To ﬁrst investigate the relationship between miR-21 and S100P
expression, we accessed whether changes in S100P expression
could alter miR-21 levels in colon cancer cells. Studies by our group
have previously shown that LS174T cells express S100P protein
and knockdown of S100P affects cell proliferation and motility
[9]. Interestingly, knock-down of S100P in LS174T cells form
smooth colonies lacking ﬁlopodia formation compared to the con-
trols, whereas over-expression of S100P in LS174T cells have the
opposite effect. S100P over-expression induces ﬁlopodia formation
and invasion of cells into the surrounding collagen (Supplemental
Fig. S1A). S100P overexpressing in both LS174T and SW480 cells
also display a more invasive phenotype (Supplemental Fig. S1B).These data are in agreement with previous ﬁndings regarding the
effects of genetic maninpulation of S100P levels in colon cancer
cells [9,10,22,23]. The knockdown of S100P led to reduced
miR-21 levels in the LS174T cells (Fig. 1A). We also found that
the over expression of S100P resulted in signiﬁcant elevation of
miR-21 in LS174T cells (Fig. 1B). These data suggest that S100P
may regulate miR-21 expression in human colon cancer cells.
Because extracellular S100P can regulate microRNA expression
via the RAGE [8], we evaluated whether S100P control of miR-21
expression is RAGE mediated. Previous studies demonstrated that
SW480 cells express the RAGE but not S100P protein [10].
SW480 cells were treated with puriﬁed human recombinant
S100P for different time points and analyzed for changes in
miR-21 expression using qRT-PCR. The levels of miR-21 began to
increase within 20 min after exposure to recombinant S100P and
were maximal at 1 h after S100P treatment. A similar rapid
induction of pri-miR-21 and miR-21 expression has been
observed in human hepatocellular carcinoma cells treated with
Dehydroepiandrosterone (DHEA) [24]. Blocking anti-RAGE anti-
body attenuated recombinant S100P induction of miR-21 at the
time points tested (Fig. 1C). Collectively, these results indicate that
the stimulation of miR-21 by S100P is RAGE dependent.
3.2. S100P/RAGE transcriptionally regulates miR-21 promoter through
AP-1
Using the ChIP bioinformatics, MAPPER (Multi-genome Analysis
of Positions and Patterns of Elements of Regulation), which combi-
nes TRANSFAC and JASPAR matrices (http://mapper.chip.org/), we
found ten AP-1 (four of them previously reported and mutated
[16]) and seven NF-kB binding sites (data not shown). We con-
ﬁrmed our previous observation that extracellular S100P could
stimulate both ERK and NF-kB signaling pathways (Fig. 2A) [8].
Next, we analyzed the effect of pharmacologic blockage on S100P
stimulation of miR-21 in colon cancer cells. We found that both
U0126 and CAY10512 reduce miR-21 expression compared to con-
trols (Fig. 2B). To further elucidate the involvement of AP-1 and
NF-kB in S100P-mediated induction of miR-21, we measured luci-
ferase activity of S100P induced SW480 cells transfected with con-
structs containing either wild type (WT), or mutated AP-1 binding
sequences (AP-1/I, AP-1/II, AP-1/III) or mutated AP-1 and NF-kB
sequences of the pri-miR-21 promoter (AP-1/I, AP-1/II, AP-1/III,
AP-1/IV and NF-kappa B) (Fig. 3A). These results show that S100P
decreases the activity of mutated pri-miR-21 promoter compared
to WT construct at 24 h (Fig. 3B). We observed a similar induction
of pri-miR-21 promoter induction in LS174T and SW480 cells over
expressing S100P (Supplemental Fig. S2). These data suggest that
S100P/RAGE signaling activates the pri-miR-21 promoter via
AP-1. To verify these observations, we performed Chip assays in
SW480 stimulated with S100P at the indicated time points. The
results showed that S100P treatment enhanced c-Fos occupancy
of the pri-miR-21 promoter at 2 h (Fig. 3C). In contrast, p-p65 does
not bind to the pri-miR-21 promoter (data not shown). Taken
together, these data show that S100P stimulate expression of
miR-21 via AP-1 signaling.
3.3. S100P, RAGE, miR-21, and RECK expression in human colon
cancers
MicroRNA-21 (miR-21) targets key genes such as RECK.
Reversion-inducing cysteine-rich protein with Kazal motifs
(RECK) is a tumor and metastasis suppressor gene, that is central
for regulating invasive and metastatic tumor cell activity. RECK is
an enzyme that regulates MMP-9 expression and is down-
regulated in certain malignancies, and its expression is positively
correlated with cancer patient survival [25]. We found that
Fig. 1. S100P/RAGE signaling induces miR-21 expression. (A) S100P knock-down in LS174T decreases miR-21 mRNA levels. (B) S100P over-expression increases signiﬁcantly
miR-21 expression in LS174T colon cancer cells. (C) Induction of miR-21 expression at 20 min, 1 h and 2 h by hr-S100P is inhibited by anti-RAGE blocking antibody in SW480
cells. Expression levels of miR-21 were normalized to U6 levels. Error bars represent mean ± S.E.M., Statistical signiﬁcance was calculated using two tailed Student’s t-test,
P < 0.05 = ⁄, P < 0.01 = ⁄⁄, P < 0.001 = ⁄⁄⁄.
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Fig. 2. S100P activates ERK and NF-kB signaling. (A) Serum-starved SW480 cells were induced with hr-S100P. Analysis of protein levels by Western blots shows activation of
ERK1/2 after 30 min of cells with S100P. AP-1 components c-fos and c-jun are activated after 2 h and 15 min of hr-S100P treatment, respectively. NF-kB (p65) activation was
on and off at 15 min and 2 h, respectively. Hr-S100P treatment increased expression of total c-fos (T-c-fos) at 15 min and total p-65 at 1 h. Laminin B is the sample loading
control. (B) qRT-PCR analysis of SW480 cells induced with hr-S100P and treated with U0126 and CAY10512 inhibit ERK1/2 and NF-kB respectively, showing about 50%
decrease in miR-21 expression levels. Error bars represent mean ± S.E.M., statistical signiﬁcance was calculated using two tailed Student’s t-test, P < 0.05 = ⁄, P < 0.01 = ⁄⁄,
P < 0.001 = ⁄⁄⁄.
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levels in colon cancer cells (Supplemental Fig. S3).
3.4. TCGA expression data
Given the role of the S100P/RAGE/miR-21 role in tumor pro-
gression and metastasis, we sought to determine the relationship
of the S100P/RAGE/miR-21 and RECK in human colon cancer by
mining The Cancer Genome Atlas (TCGA) database. Expression
analysis revealed that S100P, RAGE (Advanced glycation endpro-
duct receptor, gene encoding RAGE (AGER)), and miR-21 were sig-
niﬁcantly over-expressed in primary tumors (n = 347) compared to
normal control tissues (n = 47). Whereas, the miR-21 target gene
RECK was expressed in normal controls and decreased in cancer
cases (Fig. 4). This inference is consistent with our in vitro ﬁndings.
Furthermore, previous studies have shown that high expression of
S100P and miR-21 are associated with decreased survival [13,26].
4. Discussion
A key characteristic of malignant colon cancer includes the abil-
ity to invade and metastasize. The molecular mechanisms and
pathologic process involved in metastasis are beginning to be elu-
cidated. Examples include the inﬂammatory microenvironmentwhich appears to be a critical factor in the dysregulation of
microRNA expression [14].
In the present study, we demonstrate that activation of the
S100P/RAGE signaling can lead to the up-regulation of oncogenic
miR-21 via AP-1 signaling pathway. Our previous studies show
that the expression of S100P can be stimulated by inﬂammatory
prostaglandin E2 (PGE2) [9]. These data are consistent with previ-
ous ﬁndings demonstrating a functional role of miR-21 in colon
cancer progression and important role of inﬂammation in enhanc-
ing miR-21 expression [14,20,27]. Results presented in this article
indicate for the ﬁrst time that S100P/RAGE signaling may be
upstream factor that can inﬂuence the expression of oncogenic
miR-21.
Increased expression levels of miR-21 have been found in many
typesofhumancancers includingcoloncancer [15]. Additional stud-
ies have demonstrated an association between elevated levels of
miR-21 and down-regulation of several target genes, such as
PDCD4, TIMP3, PTEN, Sprouty, and RECK [16–18]. Our in vitro
studies, bioinformatic analysis of the TCGA database, and
Western blot analysis demonstrate that the activation of the
S100P/RAGE/miR-21 pathway can lead to the downregulation of
RECK. Since RECK serves as an inhibitor of metalloproteinase activi-
ties of MT1-MMP, MMP-2 and MMP-9 [28–30], the repression of
RECK could lead to increased metalloproteinase activities in cells
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Fig. 4. Expression analysis of S100P, RAGE, miR-21, and RECK in primary colorectal tumors using the TCGA database. Exon expression analysis of S100P, RAGE, miR-21 and
RECK in the TCGA dataset of colorectal adenocarcinoma (COADREAD) was performed by HiSeq Illumina sequencing of RNA samples obtained from fresh frozen tissues of
primary colorectal tumors (in red, n = 347) and normal solid tissues (in green, n = 47). Red and blue in gene expression dataset represent over- and under-expression,
respectively. The heatmap indicates increased expression of S100P, RAGE, and miR-21 and decreased expression of RECK in primary tumors compared to normal tissue.
Statistical analysis was performed using Student’s t-test with Benjamini-Hochberg correction with P < 0.05 considered as statistically signiﬁcant.
2392 M.E. Mercado-Pimentel et al. / FEBS Letters 589 (2015) 2388–2393allowing the remodeling of ECM and consequently facilitating the
onset of invasion and metastasis. Our studies are the ﬁrst to show
that S100P/RAGE signaling up-regulates miR-21 expression whichcould potentially lead to RECK repression, suggesting a role in the
rearrangement or dissociation of cell-ECM interactions (Fig. 5).
However, further more detailed studies are required.
S100P 
RAGE 
miR-21 
ERK1/2 activation 
Tumor invasion 
and Metastasis 
AP-1 activation 
RECK 
Fig. 5. Proposed model of how S100P/RAGE signaling can promote colorectal cancer
progression by linking inﬂammation to RECK down-regulation via the induction of
miR-21.
M.E. Mercado-Pimentel et al. / FEBS Letters 589 (2015) 2388–2393 2393Although extracellular S100P/RAGE signaling has been impli-
cated in metastasis, our results further indicate that S100P/RAGE
signaling can regulate expression of oncogenic miR-21. In addition,
the regulation of miR-21 expression by S100P/RAGE signaling
appears to be AP-1 dependent. Furthermore, our results support
the notion that S100P could be a biomarker of early metastatic pro-
cesses and functional blocking of extracellular S100P/RAGE signal-
ing might be efﬁcient for the treatment of metastatic disease.
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